Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Imricor Medical Systems Announces First Procedures in Clinical Study of MR-Enabled™Cardiac Ablation Products


News provided by

Imricor Medical Systems, Inc.

09 Oct, 2014, 14:34 GMT

Share this article

Share toX

Share this article

Share toX

- First patients treated with Vision-MR™Ablation Catheters

MINNEAPOLIS, Oct. 9, 2014 /PRNewswire/ -- Imricor Medical Systems, Inc. announced the first three cardiac ablation procedures were completed in the first clinical study that is evaluating the feasibility of their MR-enabledTM products to treat atrial flutter. Professor Reza Razavi, Head of the Division of Imaging Sciences & Biomedical Engineering, King's College London, is the principal investigator for the study and along with Mark O'Neill, Professor of Cardiac Electrophysiology and Consultant Cardiologist, Guy's and St. Thomas' NHS Trust performed the procedures. The prospective pilot study will enroll up to 15 patients at this center.

Continue Reading
This image opens in the lightbox
Mark O'Neill, Professor of Cardiac Electrophysiology and Consultant Cardiologist at King's College London, performing a cardiac catheter ablation procedure with Imricor Medical Systems MR-enabled cardiac ablation products. (PRNewsFoto/Imricor Medical Systems, Inc.) (PRNewsFoto/Imricor Medical Systems, Inc.)
This image opens in the lightbox
Professor Reza Razavi, Head of the Division of Imaging Sciences & Biomedical Engineering, and Mark O'Neill, Professor of Cardiac Electrophysiology and Consultant Cardiologist, from King's College London. (PRNewsFoto/Imricor Medical Systems, Inc.) (PRNewsFoto/Imricor Medical Systems, Inc.)
This image opens in the lightbox
Imricor Medical Systems, Inc. (PRNewsFoto/Imricor Medical Systems, Inc.) (PRNewsFoto/Imricor Medical Systems, Inc.)

Photo - http://photos.prnewswire.com/prnh/20141006/150490
Photo - http://photos.prnewswire.com/prnh/20141006/150489
Logo - http://photos.prnewswire.com/prnh/20141006/150501

The Vision-MR™ Ablation Catheter and Advantage-MR™ EP Recorder/Stimulator System are currently being evaluated for the treatment of atrial flutter. The Vision-MR™ Ablation Catheter looks, feels, and functions like a conventional ablation catheter, but its patented technology makes it uniquely MR-enabled. The Advantage-MR™ EP Recording/Stimulator System is also MR-enabled to avoid dangerous electromagnetic interactions with the MRI scanner and provide clear intra-cardiac electrograms and interference-free MR images. The system delivers the needed MR-enabled recording and pacing functions. Both products are used in conjunction with the iSuite image guidance platform that is provided by Philips.

"The team at King's College London and St Thomas' Hospital has been thrilled to work alongside Imricor and Philips Research to develop the novel MR-guided ablation system. There have been many technical advances that have gone into this technology in order to create a system suitable for clinical use, and it has performed extremely well in the early phases of clinical trials. This is a groundbreaking study and we believe that there is a great future for MR-guided heart rhythm interventions. Not only is the requirement for x-rays removed, but for the first time the clinician is able to see the detailed anatomy of the heart, in real-time, during the procedure, and the therapeutic ablation lesions that have been created. The impact that such information could have on complex ablation procedures is enormous. We hope that this is a great step forward in the care and treatment of patients with abnormal heart rhythms," said Professor Razavi.

"We are very excited to work with Drs. Razavi and O'Neill and the rest of their team, as well as Philips Research, to make this long awaited dream of MR-guided cardiac ablations a reality. Imricor is the world leader in developing MR-guided interventional products for electrophysiology, and this study marks a quantum step forward for the field," said Steve Wedan, Imricor's President and Chief Executive Officer.

About Imricor Medical Systems
Imricor Medical Systems is a privately held company that specializes in developing devices and systems that are compatible with magnetic resonance imaging (MRI). Its unique MR-enabled interventional products are designed to provide doctors the ability to perform interventional procedures while taking advantage of the superior soft tissue imaging capabilities of MRI. Imricor is the world leader in the development of MR-enabled devices for electrophysiology applications. Imricor also licenses its technology to help make implanted medical devices compatible with MRI.

For more information, please visit www.imricor.com.

Contact Information

Jodi Lloyd, Communications Manager, Imricor Medical Systems, Inc.
400 Gateway Blvd. Burnsville, MN 55337
Phone: +1 952.818.8417; e-mail: info@imricor.com

CAUTION: Vision-MRTM Ablation Catheter and Advantage-MRTM EP Recorder/Stimulator System have been approved as investigational devices for clinical studies in Europe.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.